MX2012004264A - Derivados de sulfoxidos para el tratamiento de tumores. - Google Patents

Derivados de sulfoxidos para el tratamiento de tumores.

Info

Publication number
MX2012004264A
MX2012004264A MX2012004264A MX2012004264A MX2012004264A MX 2012004264 A MX2012004264 A MX 2012004264A MX 2012004264 A MX2012004264 A MX 2012004264A MX 2012004264 A MX2012004264 A MX 2012004264A MX 2012004264 A MX2012004264 A MX 2012004264A
Authority
MX
Mexico
Prior art keywords
treating tumors
sulfoxide derivatives
sulfoxide
derivatives
tautomers
Prior art date
Application number
MX2012004264A
Other languages
English (en)
Inventor
Kai Schiemann
Wolfgang Staehle
Melanie Schultz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2012004264A publication Critical patent/MX2012004264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de sulfóxido de la fórmula la a Im tal como se describió, así como sus sales, solvatos, enantiómeros, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones para el tratamiento de tumores.
MX2012004264A 2009-10-13 2010-09-14 Derivados de sulfoxidos para el tratamiento de tumores. MX2012004264A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009049211A DE102009049211A1 (de) 2009-10-13 2009-10-13 Sulfoxide
PCT/EP2010/005641 WO2011044978A1 (de) 2009-10-13 2010-09-14 Sulfoxidederivate zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
MX2012004264A true MX2012004264A (es) 2012-05-22

Family

ID=43242294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004264A MX2012004264A (es) 2009-10-13 2010-09-14 Derivados de sulfoxidos para el tratamiento de tumores.

Country Status (16)

Country Link
US (1) US8552001B2 (es)
EP (1) EP2488504B1 (es)
JP (1) JP5816182B2 (es)
KR (1) KR20120083445A (es)
CN (1) CN102712604B (es)
AR (1) AR078613A1 (es)
AU (1) AU2010306184B2 (es)
BR (1) BR112012008546A2 (es)
CA (1) CA2777283C (es)
DE (1) DE102009049211A1 (es)
EA (1) EA201200578A1 (es)
ES (1) ES2602203T3 (es)
IL (1) IL218971A (es)
MX (1) MX2012004264A (es)
WO (1) WO2011044978A1 (es)
ZA (1) ZA201203449B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
CA2895448A1 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
MX2016006623A (es) 2013-11-22 2017-03-10 Pharmakea Inc Compuestos de inhibidor de autotaxina.
US9926318B2 (en) 2013-11-22 2018-03-27 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EA036337B1 (ru) 2015-05-27 2020-10-28 Сабре Терапьютикс Ллс Ингибиторы аутотаксина и их применения
CN112778274B (zh) * 2019-11-05 2022-02-15 四川海思科制药有限公司 一种含氮杂环衍生物及其制备
CN117980300A (zh) 2021-09-21 2024-05-03 明斯特大学 自分泌运动因子抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491066A1 (fr) 1980-09-29 1982-04-02 Cerm Cent Europ Rech Mauvernay Benzoxazolinones substituees en 6 par une chaine aminoalcool ou aminocetone, leur preparation et leur application en therapeutique
FR2637286A1 (fr) 1988-10-04 1990-04-06 Adir Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2643634A1 (fr) 1989-02-28 1990-08-31 Adir Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
DK0709384T3 (da) 1994-10-31 1999-08-23 Merck Patent Gmbh Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
DE10050236A1 (de) 2000-10-11 2002-04-25 Merck Patent Gmbh Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
EP1736474A4 (en) 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
DE102007047735A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate

Also Published As

Publication number Publication date
DE102009049211A1 (de) 2011-04-28
JP2013507403A (ja) 2013-03-04
ZA201203449B (en) 2013-01-31
CA2777283C (en) 2017-11-21
US20120202827A1 (en) 2012-08-09
ES2602203T3 (es) 2017-02-20
AR078613A1 (es) 2011-11-23
EP2488504B1 (de) 2016-07-06
KR20120083445A (ko) 2012-07-25
IL218971A0 (en) 2012-07-31
CN102712604A (zh) 2012-10-03
US8552001B2 (en) 2013-10-08
AU2010306184B2 (en) 2016-08-11
JP5816182B2 (ja) 2015-11-18
CA2777283A1 (en) 2011-04-21
EP2488504A1 (de) 2012-08-22
EA201200578A1 (ru) 2012-11-30
IL218971A (en) 2017-11-30
BR112012008546A2 (pt) 2016-04-05
CN102712604B (zh) 2015-04-08
AU2010306184A1 (en) 2012-05-31
WO2011044978A1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
UA105911C2 (uk) Сульфонамідні похідні
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
MY150699A (en) 5-substituted quinazolinone derivatives as antitumor agents
MX346608B (es) Compuestos de isoindol 5-sustituidos.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MY181898A (en) Heterocyclic compounds and uses thereof
HK1157329A1 (en) Piperidinyl gpcr agonists
IN2012DN03182A (es)
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
PH12015501088A1 (en) Dimeric compounds
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
TN2011000355A1 (en) Novel microbiocides
NZ594186A (en) Indole derivatives as anticancer agents
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
PH12015500399A1 (en) Azaindolines
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives